GO
Loading...

Regeneron Pharmaceuticals Inc

More

  • TRENTON, N.J.— Amgen Inc. boosted its first-quarter profit by 51 percent, thanks to surging drug sales and ongoing cost cuts designed to free up cash for an unprecedented burst of new product launches. Amgen reported net income of $1.62 billion, or $2.11 per share, up from $1.07 billion, or $1.40 per share, in 2014' s first quarter. Adjusted net income, excluding...

  • Worst 5 stocks of the week. Here's how to trade them Friday, 27 Mar 2015 | 1:23 PM ET

    CNBC Pro highlights the worst-performing stocks this week and analyzes whether the negative momentum will continue.

  • March 27- Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares plunging 64 percent in premarket trading on Friday. The study tested the eye-drop solution, OHR-102, in combination with Roche Holding AG's injectable eye drug Lucentis, in patients with the wet...

  • Lightning Round: Problem with Visa's split Tuesday, 24 Mar 2015 | 7:33 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • March 23- Pfizer Inc and Eli Lilly and Co will resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial hold on it. Pfizer expects to receive a $200 million upfront payment from Lilly as a result of the development, the companies said on Monday. In 2013, Pfizer forged a deal with Lilly to jointly develop...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • Cramer Remix: Cha-ching! Time to cash in Friday, 20 Mar 2015 | 7:26 PM ET
    Jim Cramer on the set of Mad Money

    “Mad Money” host Jim Cramer on why this rally won’t last forever and why you should take some off the table on this.

  • Top 5 stocks of the week and how to trade them Friday, 20 Mar 2015 | 12:55 PM ET
    American Airlines

    CNBC Pro highlights the top performing stocks this week and analyzes whether the good times will continue.

  • Cramer: Snap up this incredible opportunity Thursday, 19 Mar 2015 | 6:22 PM ET
    Lab technician handling test tubes

    Jim Cramer can't believe how Esperion Therapeutics stock has shot through the roof! Can it keep going?

  • Cramer Remix: Oil news you've been waiting for Wednesday, 18 Mar 2015 | 7:34 PM ET
    Jim Cramer on Mad Money.

    You’ve been waiting months for the answer on oil, “Mad Money” host Jim Cramer’s got the answer.

  • Cramer: This sector has tons of hidden opportunity Monday, 16 Mar 2015 | 6:17 PM ET
    Biotech

    Jim Cramer is seeing an unusual trend in the market lately, which has set these stocks on fire.

  • New cholesterol drugs cut heart attack risk in half Monday, 16 Mar 2015 | 8:44 AM ET
    Amgen

    Studies of a new class of cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack.

  • An analysis of about 4,500 patients who stayed on treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of those given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group on standard treatment, which ranged from diet changes to...

  • An analysis of about 4,500 patients who continued treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of patients given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group receiving standard treatment, which ranged from...

  • Cramer's Top 10 performers from the past 10 years Friday, 13 Mar 2015 | 6:56 PM ET
    Netflix

    Jim Cramer put his research hat on and found the Top 10 performers in the past decade.

  • Cramer's game plan: Biggest fear on the dollar Friday, 13 Mar 2015 | 6:11 PM ET
    A man walks past Petrobras headquarters, Brazil's state-run oil company, March 9, 2015, in Rio de Janeiro.

    Jim Cramer sees one company out there that could be big trouble if the U.S. dollar keeps strengthening.

  • These cholesterol drugs stocks are poised to move Friday, 13 Mar 2015 | 3:33 PM ET
    Surgeons performing operation

    Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.

  • Lightning Round: Good chance this is downgraded Thursday, 12 Mar 2015 | 8:07 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer Remix: An Apple anniversary surprise Thursday, 12 Mar 2015 | 8:03 PM ET
    Jim Cramer speaks with Apple Inc. CEO Tim Cook on the 10th Anniversary of Mad Money.

    Apple CEO Tim Cook gives “Mad Money” host Jim Cramer the surprise of his career for his big 10th Anniversary show